Literature DB >> 23802659

Rituximab pharmacokinetics in children and adolescents with de novo intermediate and advanced mature B-cell lymphoma/leukaemia: a Children's Oncology Group report.

Matthew J Barth1, Stanton Goldman, Lynette Smith, Sherrie Perkins, Bruce Shiramizu, Thomas G Gross, Lauren Harrison, Warren Sanger, Mark B Geyer, Lisa Giulino-Roth, Mitchell S Cairo.   

Abstract

The ANHL01P1 trial was undertaken to determine pharmacokinetics and safety following the addition of rituximab to French-American-British/Lymphome Malins de Burkitt (FAB/LMB96) chemotherapy in 41 children and adolescents with Stage III/IV mature B-cell lymphoma/leukaemia. Patients received rituximab (375 mg/m(2) ) days -2 and 0 of two induction cycles and day 0 of two consolidation cycles. Highest peak levels were achieved following the second dose of each induction cycle [299 ± 19 and 384 ± 25 μg/ml (Group-B); 245 ± 31 and 321 ± 32 μg/ml (Group-C)] with sustained troughs and t½ of 26-29 d. Rituximab can be safely added to FAB chemotherapy with high early rituximab peak/trough levels and a long t½.
© 2013 John Wiley & Sons Ltd.

Entities:  

Keywords:  CD20; non-Hodgkin lymphoma; pediatric; pharmacokinetics; rituximab

Mesh：

Substances：

Year:  2013        PMID： 23802659      PMCID： PMC3745786          DOI： 10.1111/bjh.12434

Source DB:  PubMed          Journal:  Br J Haematol        ISSN： 0007-1048            Impact factor:   6.998


  13 in total

1.  IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma.

Authors:  D G Maloney; A J Grillo-López; C A White; D Bodkin; R J Schilder; J A Neidhart; N Janakiraman; K A Foon; T M Liles; B K Dallaire; K Wey; I Royston; T Davis; R Levy
Journal:  Blood       Date:  1997-09-15       Impact factor: 22.113

2.  CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma.

Authors:  Bertrand Coiffier; Eric Lepage; Josette Briere; Raoul Herbrecht; Hervé Tilly; Reda Bouabdallah; Pierre Morel; Eric Van Den Neste; Gilles Salles; Philippe Gaulard; Felix Reyes; Pierre Lederlin; Christian Gisselbrecht
Journal:  N Engl J Med       Date:  2002-01-24       Impact factor: 91.245

3.  Advanced stage, increased lactate dehydrogenase, and primary site, but not adolescent age (≥ 15 years), are associated with an increased risk of treatment failure in children and adolescents with mature B-cell non-Hodgkin's lymphoma: results of the FAB LMB 96 study.

Authors:  Mitchell S Cairo; Richard Sposto; Mary Gerrard; Anne Auperin; Stanton C Goldman; Lauren Harrison; Ross Pinkerton; Martine Raphael; Keith McCarthy; Sherrie L Perkins; Catherine Patte
Journal:  J Clin Oncol       Date:  2012-01-03       Impact factor: 44.544

4.  Prospective phase 1/2 study of rituximab in childhood and adolescent chronic immune thrombocytopenic purpura.

Authors:  Carolyn M Bennett; Zora R Rogers; Daniel D Kinnamon; James B Bussel; Donald H Mahoney; Thomas C Abshire; Hadi Sawaf; Theodore B Moore; Mignon L Loh; Bertil E Glader; Maggie C McCarthy; Brigitta U Mueller; Thomas A Olson; Adonis N Lorenzana; William C Mentzer; George R Buchanan; Henry A Feldman; Ellis J Neufeld
Journal:  Blood       Date:  2005-12-13       Impact factor: 22.113

5.  Results of a randomized international study of high-risk central nervous system B non-Hodgkin lymphoma and B acute lymphoblastic leukemia in children and adolescents.

Authors:  Mitchell S Cairo; Mary Gerrard; Richard Sposto; Anne Auperin; C Ross Pinkerton; Jean Michon; Claire Weston; Sherrie L Perkins; Martine Raphael; Keith McCarthy; Catherine Patte
Journal:  Blood       Date:  2007-04-01       Impact factor: 22.113

6.  Results of the randomized international FAB/LMB96 trial for intermediate risk B-cell non-Hodgkin lymphoma in children and adolescents: it is possible to reduce treatment for the early responding patients.

Authors:  Catherine Patte; Anne Auperin; Mary Gerrard; Jean Michon; Ross Pinkerton; Richard Sposto; Claire Weston; Martine Raphael; Sherrie L Perkins; Keith McCarthy; Mitchell S Cairo
Journal:  Blood       Date:  2007-04-01       Impact factor: 22.113

7.  Pediatric dosing of rituximab revisited: serum concentrations in opsoclonus-myoclonus syndrome.

Authors:  Michael R Pranzatelli; Elizabeth D Tate; Steven J Verhulst; Salvatore J Bertolone; Deepika Bhatla; Meaghan Granger; Joseph Lebowizc; Sharon K Lockhart; Joseph M Wiley
Journal:  J Pediatr Hematol Oncol       Date:  2010-07       Impact factor: 1.289

8.  Rituximab serum concentrations during immuno-chemotherapy of follicular lymphoma correlate with patient gender, bone marrow infiltration and clinical response.

Authors:  Ulrich Jäger; Michael Fridrik; Markus Zeitlinger; Daniel Heintel; Georg Hopfinger; Sonja Burgstaller; Christine Mannhalter; Wilhelm Oberaigner; Edit Porpaczy; Cathrin Skrabs; Christine Einberger; Johannes Drach; Markus Raderer; Alexander Gaiger; Monique Putman; Richard Greil
Journal:  Haematologica       Date:  2012-04-17       Impact factor: 9.941

9.  Feasibility and pharmacokinetic study of a chimeric anti-CD20 monoclonal antibody (IDEC-C2B8, rituximab) in relapsed B-cell lymphoma. The IDEC-C2B8 Study Group.

Authors:  K Tobinai; Y Kobayashi; M Narabayashi; M Ogura; Y Kagami; Y Morishima; T Ohtsu; T Igarashi; Y Sasaki; T Kinoshita; T Murate
Journal:  Ann Oncol       Date:  1998-05       Impact factor: 32.976

10.  Rituximab and FAB/LMB 96 chemotherapy in children with Stage III/IV B-cell non-Hodgkin lymphoma: a Children's Oncology Group report.

Authors:  S Goldman; L Smith; J R Anderson; S Perkins; L Harrison; M B Geyer; T G Gross; H Weinstein; S Bergeron; B Shiramizu; W Sanger; M Barth; J Zhi; M S Cairo
Journal:  Leukemia       Date:  2012-09-03       Impact factor: 11.528
View more
  12 in total

Review 1.  Mechanisms of Resistance to Monoclonal Antibodies (mAbs) in Lymphoid Malignancies.

Authors:  Pallawi Torka; Mathew Barth; Robert Ferdman; Francisco J Hernandez-Ilizaliturri
Journal:  Curr Hematol Malig Rep       Date:  2019-10       Impact factor: 3.952

2.  Comparative genomic expression signatures of signal transduction pathways and targets in paediatric Burkitt lymphoma: a Children's Oncology Group report.

Authors:  Sanghoon Lee; Nancy S Day; Rodney R Miles; Sherrie L Perkins; Megan S Lim; Janet Ayello; Carmella van de Ven; Lauren Harrison; Nader K El-Mallawany; Stanton Goldman; Mitchell S Cairo
Journal:  Br J Haematol       Date:  2017-05-04       Impact factor: 6.998

3.  Rituximab with chemotherapy in children and adolescents with central nervous system and/or bone marrow-positive Burkitt lymphoma/leukaemia: a Children's Oncology Group Report.

Authors:  Stanton Goldman; Lynette Smith; Paul Galardy; Sherrie L Perkins; John Kimble Frazer; Warren Sanger; James R Anderson; Thomas G Gross; Howard Weinstein; Lauren Harrison; Bruce Shiramizu; Matthew Barth; Mitchell S Cairo
Journal:  Br J Haematol       Date:  2014-07-26       Impact factor: 6.998

Review 4.  [Malignant lymphomas in children and adolescents. Practical knowledge for diagnosis].

Authors:  I Oschlies; W Klapper
Journal:  Pathologe       Date:  2014-07       Impact factor: 1.011

5.  Overall survival of children and adolescents with mature B cell non-Hodgkin lymphoma who had refractory or relapsed disease during or after treatment with FAB/LMB 96: A report from the FAB/LMB 96 study group.

Authors:  Mitchell Cairo; Anne Auperin; Sherrie L Perkins; Ross Pinkerton; Lauren Harrison; Stanton Goldman; Catherine Patte
Journal:  Br J Haematol       Date:  2018-07-09       Impact factor: 6.998

Review 6.  Management of Aggressive Non-Hodgkin Lymphomas in the Pediatric, Adolescent, and Young Adult Population: An Adult vs. Pediatric Perspective.

Authors:  Irtiza N Sheikh; Amr Elgehiny; Dristhi Ragoonanan; Kris M Mahadeo; Yago Nieto; Sajad Khazal
Journal:  Cancers (Basel)       Date:  2022-06-13       Impact factor: 6.575

7.  A multicenter phase II study incorporating high-dose rituximab and liposomal doxorubicin into the CODOX-M/IVAC regimen for untreated Burkitt's lymphoma.

Authors:  A M Evens; K R Carson; J Kolesar; C Nabhan; I Helenowski; N Islam; B Jovanovic; P M Barr; P F Caimi; S A Gregory; L I Gordon
Journal:  Ann Oncol       Date:  2013-10-20       Impact factor: 32.976

Review 8.  Pharmacokinetics and pharmacokinetic-pharmacodynamic relationships of monoclonal antibodies in children.

Authors:  Helena Edlund; Johanna Melin; Zinnia P Parra-Guillen; Charlotte Kloft
Journal:  Clin Pharmacokinet       Date:  2015-01       Impact factor: 5.577

9.  A comparative global phosphoproteomics analysis of obinutuzumab (GA101) versus rituximab (RTX) against RTX sensitive and resistant Burkitt lymphoma (BL) demonstrates differential phosphorylation of signaling pathway proteins after treatment.

Authors:  Aradhana Awasthi; Delphine C M Rolland; Janet Ayello; Carmella van de Ven; Venkatesha Basrur; Kevin Conlon; Damian Fermin; Matthew J Barth; Christian Klein; Kojo S J Elenitoba-Johnson; Megan S Lim; Mitchell S Cairo
Journal:  Oncotarget       Date:  2017-12-09

10.  Outcomes of Burkitt lymphoma with bone marrow involvement or Burkitt leukemia in Chinese children.

Authors:  Jia Zhu; Zijun Zhen; Juan Wang; Feifei Sun; Suying Lu; Junting Huang; Yizhuo Zhang; Xiaofei Sun
Journal:  Pediatr Investig       Date:  2021-06-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.